KEAP1 and cholangiocarcinoma: Moreover, it has been reported that FOXO3A can regulate chemotherapy and targeted drug resistance; for example, in cholangiocarcinoma, FOXO3A inactivation through the Keap1–Nrf2 axis leads to chemotherapy resistance [34].